| Protocol | Study Chair | Information for Patients and Families | Information for Health Professionals | Industry/Foundation Support | NCI Trial ID |
|---|---|---|---|---|---|
|
PBTC-045: A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with recurrent, progressive or refractory high-grade gliomas (HGG) and DIPGs |
Eugene Hwang, MD Children’s National Medical Center 111 Michigan Ave, NS Washington, DC 20010 Telephone: 202-476-5046 Fax: 202-476-4304 Email: [email protected] |
Summary for Patients and Families | Abstract for Health Professionals | NCT02359565 | |
| PBTC-048: Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma |
Stewart Goldman, MD Phoenix Children’s Hospital 1919 E. Thomas Road Phoenix, AZ 85016 Phone: (602) 933-5468 Email: [email protected] |
Summary for Patients and Families | Abstract for Health Professionals |
|
NCT03033992 |
| PBTC-049: A Phase I study of Savolitinib in Recurrent, Progressive, or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS tumors harboring MET aberrations |
Ralph Salloum, MD Cincinnati Children’s Hospital Medical Center 3333 Burnett Avenue Cincinnati, OH, 45229 Phone: (513) 803-1126 Fax: (513) 636-5349 Email: [email protected] |
Summary for Patients and Families | Abstract for Health Professionals | NCT03598244 | |
| PBTC-051: Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma |
Ira Dunkel, MD Memorial Sloan Kettering Cancer Center Department of Pediatrics Howard 1102 New York, NY 10065 Phone: (212) 639-2153 Fax: (212) 717-3239 Email: [email protected] |
Summary for Patients and Families | Abstract for Health Professionals |
|
NCT03389802 |
| PBTC-053: A Pediatric Brain Tumor Consortium Phase I/ II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma |
Ralph Salloum, MD Cincinnati Children’s Hospital Medical Center 3333 Burnett Avenue Cincinnati, OH, 45229 Phone: (513) 803-1126 Fax: (513) 636-5349 Email: [email protected] |
Summary for Patients and Families | Abstract for Health Professionals |
|
NCI-2019-00180 |
| PBTC-055: Phase I/II trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF fusion/duplication positive or NF1-associated recurrent or progressive gliomas in children and young adults |
Lindsey Hoffman, DO Phoenix Children's Hospital 1919 E Thomas Rd Phoenix, AZ 85016 Phone: (602) 933-0920 Fax: (602) 933-2492 Email: [email protected] |
Abstract for Health Professionals |
|
NCI-2019-06216 | |
| PBTC-056: A Phase I Study Of The Adam-10 Inhibitor, INCB7839 In Children With Recurrent/Progressive High-Grade Gliomas To Target Microenvironmental Neuroligin-3 |
Michelle Monje, MD PhD Stanford University and Lucile Packard Children's Hospital 750 Welch Road, Suite 317 Palo Alto, CA 94304 Phone: (650) 721-5750 Fax: (650) 723-7299 Email: [email protected] |
Summary for Patients and Families | Abstract for Health Professionals |
|
NCT04295759 |
| PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma |
Matthias Karajannis, MD, MS Memorial Sloan Kettering Cancer Center 1275 York Avenue, Box 234 New York, NY 10065 Phone: (212) 639-3171 Fax: (212) 717-3239 Email: [email protected] |
Summary for Patients and Families | Abstract for Health Professionals |
|
NCT04743661 |
| PBTC-059: Phase 1 Trial of Autologous HER2-specific CAR T cells in Pediatric Patients with Refractory or Recurrent Ependymoma |
Meenakshi Hegde, MD Texas Children’s Hospital 1102 Bates Ave. Suite 1770 Houston, TX 77030 Phone: (832) 824-4840 Fax: (832) 825-4732 Email: [email protected] |
|
NCT04903080 | ||
| PBTC-060: A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma |
Clare J Twist, MD Roswell Park Comprehensive Cancer Center Elm and Carlton Streets Buffalo, NY 14623 Phone: (716) 845-2333 Fax: (716) 845-8003 Email: [email protected] |
Abstract for Health Professionals |
|
NCT04978727 |
| Protocol | Study Chair | Information for Health Professionals | PubMed ID |
|---|---|---|---|
| PBTC-001:
Pilot Study of Systemic and Intrathecal Chemotherapy followed by Conformal Radiation for Infants with Embryonal Intracranial Central Nervous System Tumors |
Susan Blaney, MD |
Abstract for Health Professionals | PMC3529096 |
| PBTC-002: A Phase I Study of SU5416 in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors |
Mark W. Kieran, MD, PhD |
Abstract for Health Professionals | PMC2775441 |
| PBTC-003:
Phase I Trial of Escalating Oral Doses of SCH 66336 in Pediatric Patients with Refractory or Recurrent Brain Tumors |
Mark W. Kieran, MD, PhD |
Abstract for Health Professionals | PMID17634493 |
| PBTC-004: Phase I Study of Intrathecal SpartajectTM-Busulfan in Children with Neoplastic Meningitis |
Sri Gururangan, MRCP (UK) |
Abstract for Health Professionals | PMID16533779 |
|
PBTC-005: Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients with Recurrent Brain Tumors |
Amar J. Gajjar, MD |
Abstract for Health Professionals | PMID18006772 |
| PBTC-006: A Phase I/II Trial of STI571 in Children with Newly Diagnosed Poor Prognosis Brainstem Gliomas and Recurrent Intracranial Malignant Gliomas |
Ian F. Pollack, MD |
Abstract for Health Professionals | PMC1871662 |
|
PBTC-007: A Phase I/II Trial of ZD1839 (IressaTM) and Radiation in Pediatric Patients Newly Diagnosed with Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas with Phase II limited to Brain Stem Tumors |
J. Russell Geyer, MD |
Abstract for Health Professionals | PMC2988095 |
|
PBTC-009: Phase I Trial of GLIADEL® and O6-Benzylguanine in Pediatric Patients with Recurrent Malignant Gliomas |
Ian F. Pollack, MD |
Abstract for Health Professionals | |
| PBTC-010: A Phase II Study of Oxaliplatin in Children with Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors |
Maryam Fouladi, MD |
Abstract for Health Professionals | PMID17019740 |
|
PBTC-011C: Phase I/II Trial of Intracerebral IL13-PE38QQR Infusion in Pediatric Patients with Recurrent Malignant Glioma |
Anuradha Banerjee, MD, MPH |
Abstract for Health Professionals | |
| PBTC-012: Phase I Study of Cilengitide (EMD 121974) in Children with Refractory Brain Tumors |
Tobey MacDonald, MD |
Abstract for Health Professionals | PMID18281665 |
| PBTC-013: A Phase I/II Study of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-a and a Mutated Form of the Pseudomonas Exotoxin Termed PE38 (TP-38) in Pediatric Patients with Recurrent or Progressive Supratentorial High Grade Gliomas |
Roger Packer, MD |
Abstract for Health Professionals | |
| PBTC-014: Phase I/II Trial of Zarnestra and XRT in Pediatric Patients with Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas |
Daphne Haas-Kogan, MD |
Abstract for Health Professionals | PMC2563056 |
| PBTC-015: A Phase II Trial of O6-Benzylguanine and Temozolomide in Pediatric Patients with Recurrent or Progressive High-Grade Gliomas and Recurrent or Progressive Brainstem Tumors |
Kathy Warren, MD |
Abstract for Health Professionals | PMC3518022 |
|
PBTC-016:
A Phase I, Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients with Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma |
Maryam Fouladi, MD |
Abstract for Health Professionals | PMC2953974 |
| PBTC-017: Phase I Study of CLORETAZINE ™ (VNP4010M) in Children with Recurrent, Progressive or Refractory Primary Brain Tumors |
Sri Gururangan, MRCP (UK) |
Abstract for Health Professionals | PMID18281546 |
| PBTC-018: A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients with Recurrent or Refractory Primary CNS Tumors |
Kathy Warren, MD |
Abstract for Health Professionals | PMC3056466 |
| PBTC-019: A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Children with Neoplastic Meningitis |
Susan Blaney, MD |
Abstract for Health Professionals | PMC3573253 |
| PBTC-020: A Phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumor |
Mark Kieran, MD, PhD |
Abstract for Health Professionals | PMC4561207 |
| PBTC-021: A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas |
Susan Blaney, MD |
Abstract for Health Professionals | PMC3661085 |
| PBTC-022: Phase II study of Bevacizumab plus Irinotecan (CamptosarTM) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas |
Sri Gururangan, MRCP (UK) |
Abstract for Health Professionals | PMC2903337 |
| PBTC-023: Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors |
Susan Blaney, MD |
Abstract for Health Professionals | PMC4288513 |
| PBTC-024: A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies |
Maryam Fouladi, MD |
Abstract for Health Professionals | PMC3179253 |
| PBTC-025: A Phase I Pharmacokinetic and Safety Study in Children with Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449 |
Amar J. Gajjar, MD |
Abstract for Health Professionals | PMC3856244 |
| PBTC-025B: A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults with Recurrent or Refractory Medulloblastoma |
Amar J. Gajjar, MD |
Abstract for Health Professionals | PMC4534527 |
| PBTC-026: A Feasibility Study of SAHA combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System |
Sarah Leary, MD |
Abstract for Health Professionals | PMID34935967 |
| PBTC-027: A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors |
Jack Su, MD |
Abstract for Health Professionals | PMC4232081 |
|
PBTC-029B: A Phase I and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma |
Jason Fangusaro, MD |
Abstract for Health Professionals | |
| PBTC-030: A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas |
Lindsay Kilburn, MD |
Abstract for Health Professionals | PMC5774861 |
| PBTC-031: Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients with Refractory or Recurrent CNS Tumors |
Roger Packer, MD |
Abstract for Health Professionals | PMC4330963 |
| PBTC-032: A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children with Recurrent or Refractory Medulloblastoma |
Amar J. Gajjar, MD |
Abstract for Health Professionals | PMC4534527 |
| PBTC-033: A Phase I/ II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG) |
Patricia A. Baxter, MD |
Abstract for Health Professionals | PMC7283021 |
| PBTC-037: A phase I study of intratumoral/peritumoral herpes simplex virus-1 mutant HSV1716 in patients with refractory or recurrent high grade gliomas (HGG) |
Mariko DeWire, MD |
Abstract for Health Professionals | |
| PBTC-039: A Phase II study of Peginterferon alfa-2b (PEGIntron) for pediatric patients with unresectable or recurrent craniopharyngioma |
Stewart Goldman, MD |
Abstract for Health Professionals | PMC7690365 |
| PBTC-041: A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors |
Stewart Goldman, MD |
Abstract for Health Professionals | PMC4999001 |
| PBTC-042: Phase I study of CDK 4-6 inhibitor PD- 0332991 (palbociclib; IBRANCE) in children with recurrent, progressive or refractory central nervous system tumors |
David Van Mater, MD, PhD |
Abstract for Health Professionals | PMC8414988 |
| PBTC-043: A Phase I Trial of Pomalidomide for children with recurrent, progressive or refractory CNS tumors |
Jason Fangusaro, MD |
Abstract for Health Professionals | PMC7757731 |
| PBTC-047: A Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma |
Michelle Monje, MD PhD |
Abstract for Health Professionals | |
| PBTC-050: A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children with Recurrent or Refractory Malignant Brain Tumors |
Mariko DeWire-Schottmiller, MD |
Abstract for Health Professionals | PMC8132306 |
